Trials / Completed
CompletedNCT02344849
Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction
An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Pharmicell Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.
Detailed description
Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days. Ten patients (Diabetes -associated ED; 5 patients, Postprostatectomy; 5patients) will be injected Cellgram-ED directly into the intracavernous. Patient will be evaluated the safety and potential efficacy of MSC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mesenchymal stem cell | Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2018-01-31
- Completion
- 2018-04-01
- First posted
- 2015-01-26
- Last updated
- 2019-01-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02344849. Inclusion in this directory is not an endorsement.